AMLX
Amylyx Pharmaceuticals, Inc.
$12.19
-0.12
(-0.97%)
| Exchange: | NASDAQ |
| Market Cap: | 1.138B |
| Shares Outstanding: | 56.466M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Joshua B. Cohen | |||||
| Full Time Employees: | 123 | |||||
| Address: |
|
|||||
| Website: | https://amylyx.com |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company’s product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
Could not create stock discussion for AMLX
